Boehringer Ingelheim has entered a license agreement with Germany-based Prime Vector Technologies GmbH (PVT) to acquire exclusive rights to its Orf virus (ORFV) viral vector platform for oncology applications, adding a clinically validated cancer vaccine vector to its immuno-oncology portfolio. The ORFV platform, a parapoxvirus-based delivery system that has progressed through GMP manufacturing and Phase I/IIa clinical evaluation in infectious diseases, is designed to support off-the-shelf cancer vaccine development across multiple tumor types. The deal represents PVT's first major pharma licensing transaction since its 2019 founding as a University of Tübingen spin-out.
Financial terms were not disclosed, though PVT is eligible to receive an upfront payment, development, regulatory, and commercial milestone payments, plus royalties on future product sales.
Deal context
The ORFV platform uses the Orf virus — a parapoxvirus — as a biological backbone to deliver tumor antigens to the immune system. Parapoxviruses are known to induce strong innate immune activation that promotes downstream T-cell and antibody responses.for potent innate immune activation. ORFV has low seroprevalence in humans, reducing the risk of pre-existing neutralizing antibodies that can blunt repeat dosing — a meaningful advantage over adenovirus-based vectors. The platform does not integrate into the host genome, offering a favorable safety profile relative to some competing modalities.
The platform's Phase I/IIa clinical history in infectious diseases, combined with established GMP manufacturing, provides Boehringer with a platform that has already undergone GMP manufacturing and early clinical evaluation, reducing some of the technical and manufacturing uncertainties associated with earlier-stage vector technologies. Boehringer intends to evaluate the ORFV platform both as a standalone cancer vaccine approach and in combination with assets across its oncology pipeline. PVT retains rights to use the platform in infectious diseases and other non-oncology vaccine applications — a meaningful carve-out that limits Boehringer's exclusivity to the oncology field and preserves PVT's ability to independently develop or license the platform elsewhere.